Monopar Therapeutics (MNPR) Short term Debt (2020)
Monopar Therapeutics (MNPR) posted Short term Debt of $67772.0 for Q3 2020, up 43.04% sequentially from $47379.0 in Q2 2020.
Monopar Therapeutics (MNPR) Short term Debt (2020) Analysis & Trends
Monopar Therapeutics has reported Short term Debt for 1 years, with the latest figure at $67772.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 67,772.00 |
| Jun 30, 2020 | 47,379.00 |